1. Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry 2004;26:13–17.
2. Rive MM, van Rooijen G, Veltman DJ, Phillips ML, Schene AH, Ruhe HG. Neural correlates of dysfunctional emotion regulation in major depressive disorder. A systematic review of neuroimaging studies. Neurosci Biobehav Rev 2013;37:2529–2553.
3. McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety 2013;30:515–527.
4. World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017.
5. Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012;379:1045–1055.
7. Marchand WR, Yurgelun-Todd D. Striatal structure and function in mood disorders: a comprehensive review. Bipolar Disord 2010;12:764785
8. Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 1997;9:471–481.
9. Pizzagalli DA. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011;36:183–206.
10. Ashburner J, Friston KJ. Voxel-based morphometry--the methods. Neuroimage 2000;11:805–821.
11. Bora E, Fornito A, Pantelis C, Yucel M. Gray matter abnormalities in Major Depressive Disorder: a meta-analysis of voxel based morphometry studies. J Affect Disord 2012;138:9–18.
12. Du MY, Wu QZ, Yue Q, Li J, Liao Y, Kuang WH, et al. Voxelwise metaanalysis of gray matter reduction in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2012;36:11–16.
13. Lai CH. Gray matter volume in major depressive disorder: a metaanalysis of voxel-based morphometry studies. Psychiatry Res 2013;211:37–46.
15. Schmaal L, Veltman DJ, van Erp TG, Samann PG, Frodl T, Jahanshad N, et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. Mol Psychiatry 2016;21:806–812.
16. Schmaal L, Hibar DP, Samann PG, Hall GB, Baune BT, Jahanshad N, et al. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. Mol Psychiatry 2017;22:900–909.
17. D’Ardenne K, McClure SM, Nystrom LE, Cohen JD. BOLD responses reflecting dopaminergic signals in the human ventral tegmental area. Science 2008;319:1264–1267.
18. Gervais J, Rouillard C. Dorsal raphe stimulation differentially modulates dopaminergic neurons in the ventral tegmental area and substantia nigra. Synapse 2000;35:281–291.
19. Becker G, Becker T, Struck M, Lindner A, Burzer K, Retz W, et al. Reduced echogenicity of brainstem raphe specific to unipolar depression: a transcranial color-coded real-time sonography study. Biol Psychiatry 1995;38:180–184.
20. Becker G, Struck M, Bogdahn U, Becker T. Echogenicity of the brainstem raphe in patients with major depression. Psychiatry Res 1994;55:75–84.
21. Kostic M, Munjiza A, Pesic D, Peljto A, Novakovic I, Dobricic V, et al. A pilot study on predictors of brainstem raphe abnormality in patients with major depressive disorder. J Affect Disord 2017;209:66–70.
22. Lee HY, Tae WS, Yoon HK, Lee BT, Paik JW, Son KR, et al. Demonstration of decreased gray matter concentration in the midbrain encompassing the dorsal raphe nucleus and the limbic subcortical regions in major depressive disorder: an optimized voxel-based morphometry study. J Affect Disord 2011;133:128–136.
23. Soriano-Mas C, Hernandez-Ribas R, Pujol J, Urretavizcaya M, Deus J, Harrison BJ, et al. Cross-sectional and longitudinal assessment of structural brain alterations in melancholic depression. Biol Psychiatry 2011;69:318–325.
25. Han KM, Kim D, Sim Y, Kang J, Kim A, Won E, et al. Alterations in the brainstem volume of patients with major depressive disorder and their relationship with antidepressant treatment. J Affect Disord 2017;208:68–75.
26. Bookstein FL. “Voxel-based morphometry” should not be used with imperfectly registered images. Neuroimage 2001;14:1454–1462.
28. Bora E, Harrison BJ, Yucel M, Pantelis C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med 2013;43:2017–2026.
29. Smith R, Chen K, Baxter L, Fort C, Lane RD. Antidepressant effects of sertraline associated with volume increases in dorsolateral prefrontal cortex. J Affect Disord 2013;146:414–419.
30. Lavretsky H, Roybal DJ, Ballmaier M, Toga AW, Kumar A. Antidepressant exposure may protect against decrement in frontal gray matter volumes in geriatric depression. J Clin Psychiatry 2005;66:964–967.
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Press; 1994.
33. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971;9:97–113.
34. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988;45:742–747.
35. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278–296.
36. Park HJ, Youn T, Jeong SO, Oh MK, Kim SY, Kim EY. SENSE factors for reliable cortical thickness measurement. Neuroimage 2008;40:187196
37. Tae WS, Kim SS, Lee KU, Nam EC, Kim KW. Validation of hippocampal volumes measured using a manual method and two automated methods (FreeSurfer and IBASPM) in chronic major depressive disorder. Neuroradiology 2008;50:569–581.
39. Salimi-Khorshidi G, Smith SM, Nichols TE. Adjusting the effect of nonstationarity in cluster-based and TFCE inference. Neuroimage 2011;54:2006–2019.
41. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998;17:87–97.
42. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341–355.
43. Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004;14:11–22.
44. Benjamini Y, Hochberg Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289–300.
45. Walter U, Prudente-Morrissey L, Herpertz SC, Benecke R, Hoeppner J. Relationship of brainstem raphe echogenicity and clinical findings in depressive states. Psychiatry Res 2007;155:67–73.
46. Bessette KL, Nave AM, Caprihan A, Stevens MC. White matter abnormalities in adolescents with major depressive disorder. Brain Imaging Behav 2014;8:531–541.
47. Budisic M, Karlovic D, Trkanjec Z, Lovrencic-Huzjan A, Vukovic V, Bosnjak J, et al. Brainstem raphe lesion in patients with major depressive disorder and in patients with suicidal ideation recorded on transcranial sonography. Eur Arch Psychiatry Clin Neurosci 2010;260:203208
48. Han KM, Won E, Sim Y, Tae WS. Hippocampal subfield analysis in medication-naive female patients with major depressive disorder. J Affect Disord 2016;194:21–29.
49. Guo W, Liu F, Zhang Z, Liu J, Yu M, Zhang J, et al. Unidirectionally affected causal connectivity of cortico-limbic-cerebellar circuit by structural deficits in drug-naive major depressive disorder. J Affect Disord 2015;172:410–416.
50. Hornung JP. The human raphe nuclei and the serotonergic system. J Chem Neuroanat 2003;26:331–343.
53. van der Doelen RHA, Robroch B, Arnoldussen IA, Schulpen M, Homberg JR, Kozicz T. Serotonin and urocortin 1 in the dorsal raphe and Edinger-Westphal nuclei after early life stress in serotonin transporter knockout rats. Neuroscience 2017;340:345–358.
54. Young EA, Abelson JL, Cameron OG. Interaction of brain noradrenergic system and the hypothalamic-pituitary-adrenal (HPA) axis in man. Psychoneuroendocrinology 2005;30:807–814.
55. Chen VC, Shen CY, Liang SH, Li ZH, Tyan YS, Liao YT, et al. Assessment of abnormal brain structures and networks in major depressive disorder using morphometric and connectome analyses. J Affect Disord 2016;205:103–111.
56. Lai CH, Wu YT. The gray matter alterations in major depressive disorder and panic disorder: putative differences in the pathogenesis. J Affect Disord 2015;186:1–6.
57. Peng J, Liu J, Nie B, Li Y, Shan B, Wang G, et al. Cerebral and cerebellar gray matter reduction in first-episode patients with major depressive disorder: a voxel-based morphometry study. Eur J Radiol 2011;80:395399
58. Guillamon A, de Blas MR, Segovia S. Effects of sex steroids on the development of the locus coeruleus in the rat. Brain Res 1988;468:306310
59. Swanson LW, Hartman BK. The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. J Comp Neurol 1975;163:467–505.
60. Fast CD, McGann JP. Amygdalar gating of early sensory processing through interactions with locus coeruleus. J Neurosci 2017;37:30853101
64. Shibata E, Sasaki M, Tohyama K, Otsuka K, Sakai A. Reduced signal of locus ceruleus in depression in quantitative neuromelanin magnetic resonance imaging. Neuroreport 2007;18:415–418.
66. Chandley MJ, Szebeni A, Szebeni K, Crawford JD, Stockmeier CA, Turecki G, et al. Elevated gene expression of glutamate receptors in noradrenergic neurons from the locus coeruleus in major depression. Int J Neuropsychopharmacol 2014;17:1569–1578.
68. Saha S, Gamboa-Esteves FO, Batten TF. Differential distribution of 5-HT 1A and 5-HT 1B-like immunoreactivities in rat central nucleus of the amygdala neurones projecting to the caudal dorsomedial medulla oblongata. Brain Res 2010;1330:20–30.
69. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 2010;119:7–35.
70. Kimelberg HK. Functions of mature mammalian astrocytes: a current view. Neuroscientist 2010;16:79–106.
71. Czeh B, Di Benedetto B. Antidepressants act directly on astrocytes: evidences and functional consequences. Eur Neuropsychopharmacol 2013;23:171–185.
72. Bowley MP, Drevets WC, Ongur D, Price JL. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 2002;52:404412
74. Harrison PJ. The neuropathology of primary mood disorder. Brain 2002;125:1428–1449.
75. Riecher-Rossler A. Sex and gender differences in mental disorders. Lancet Psychiatry 2017;4:8–9.
76. Kuehner C. Why is depression more common among women than among men? Lancet Psychiatry 2017;4:146–158.
77. Kessler RC. Epidemiology of women and depression. J Affect Disord 2003;74:5–13.
78. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095–3105.
79. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593–602.
80. Kuehner C. Gender differences in unipolar depression: an update of epidemiological findings and possible explanations. Acta Psychiatr Scand 2003;108:163–174.
81. de Graaf R, ten Have M, van Gool C, van Dorsselaer S. Prevalence of mental disorders and trends from 1996 to 2009. Results from the Netherlands Mental Health Survey and Incidence Study-2. Soc Psychiatry Psychiatr Epidemiol 2012;47:203–213.
82. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:655–679.
86. Luppa M, Sikorski C, Luck T, Ehreke L, Konnopka A, Wiese B, et al. Age- and gender-specific prevalence of depression in latest-life--systematic review and meta-analysis. J Affect Disord 2012;136:212–221.